



مركز الكويت لمكافحة السرطان  
Kuwait Cancer Control Center

# ERLOtinib (Tarceva®)



\* E R L - 0 0 0 0 - D L - C N - T X \*



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m<sup>2</sup>):

**Indication(s):** First-line therapy of advanced stage ALK positive lung adenocarcinoma with EGFR ex19del or exon 21 (L858R) mutation.

**Central line:**  Available  NA

**Allergies:**  NKA  Yes, specify; \_\_\_\_\_

## Standard Protocol:

DRUG	DOSE	ADMINISTRATION
ERLOTinib	150 mg PO daily	To be given on an empty stomach at least 1hr before or 2 hr after a meal.
<b>To be given continuously until disease progression or intolerable toxicity.</b>		

**Special instructions:**

- Avoid grapefruit and grapefruit juice.
- Avoid CLARithromycin and CIPROfloxacin.
- Avoid Acid-suppressive drugs such as proton-pump inhibitors, H2 antagonists, and antacids. If taken with H2 antagonists, administer ERLOTinib 10 hrs after the H2 antagonist dose and at least 2 hrs prior to the next H2 antagonists dose.

## Treatment Description:

Cycle	Date	ERLOTinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

## Important Notes:

Reported grade 3/4 toxicities:  None  Hematological  Non-Hematological

If yes; Did it indicate hospitalization?  Yes  No

Did it indicate chemo-delay for ≥ 7 days?  Yes  No

Did it indicate dose reduction?  Yes  No

Did it indicate G-CSF support?  Yes  No